Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3662797)

Published in Melanoma Res on April 01, 2011


Vidhya Hariharan1, Timothy Toole, Jared Klarquist, Jeffrey Mosenson, B Jack Longley, I Caroline Le Poole

Author Affiliations

1: Molecular and Cellular Biochemistry Graduate Program, Loyola University Medical Center, 2160 S. 1st Avenue, Chicago, IL 60153, USA.

Articles cited by this

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47

Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25

Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis (2006) 2.20

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17

Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med (1998) 1.70

Vitiligo puzzle: the pieces fall in place. Pigment Cell Res (2007) 1.39

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39

Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun (2008) 1.31

Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (2003) 1.29

Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol (2006) 1.20

Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol (1993) 1.19

Multidrug resistance in cancer. Methods Mol Biol (2010) 1.13

HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11

Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol (1997) 1.10

Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc (2004) 1.01

Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol (1977) 1.00

Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo. Dermatology (2002) 1.00

A role for tyrosinase-related protein 1 in 4-tert-butylphenol-induced toxicity in melanocytes: Implications for vitiligo. Am J Pathol (2006) 0.95

Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Res (2003) 0.93

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Effects of contact allergens on human Langerhans cells in skin organ culture: migration, modulation of cell surface molecules, and early expression of interleukin-1 beta protein. Lab Invest (1996) 0.88

Familial melanoma. Surg Clin North Am (2008) 0.87

A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity. Chem Res Toxicol (2009) 0.86

Culture of myeloid dendritic cells from bone marrow precursors. J Vis Exp (2008) 0.84

Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer (1997) 0.83

Novel predictive assay for contact allergens using human skin explant cultures. Am J Pathol (1996) 0.82

BRCA in breast cancer: from risk assessment to therapeutic prediction. Drug News Perspect (2009) 0.80

Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet (2009) 0.79

Organotypic culture of human skin to study melanocyte migration. Pigment Cell Res (1994) 0.79

Occupational leukoderma; pinta? Arch Derm Syphilol (1948) 0.78

Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Mol Biosyst (2006) 0.78

Nonmelanoma skin cancer in vitiligo patients. J Am Acad Dermatol (2009) 0.77

Articles by these authors

Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol (2002) 20.87

Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83

Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol (2002) 2.95

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood (2002) 2.39

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol (2002) 2.19

Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis (2007) 2.16

MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res (2007) 2.08

Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78

Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66

Kikuchi's disease: case report and systematic review of cutaneous and histopathologic presentations. J Am Acad Dermatol (2008) 1.60

Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol (2008) 1.57

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol (2003) 1.55

A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50

Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol (2007) 1.50

Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42

A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev (2006) 1.41

Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology (2005) 1.32

Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis (2008) 1.29

Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J (2005) 1.28

Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol (2010) 1.27

Notch signaling regulates mouse and human Th17 differentiation. J Immunol (2011) 1.21

Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol (2006) 1.21

Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12

HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11

Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol (2008) 1.11

Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09

Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations. Am J Dermatopathol (2013) 1.02

HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res (2011) 0.97

Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94

MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression. PLoS One (2011) 0.93

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93

Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol (2014) 0.90

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol (2012) 0.89

Cutaneous adenoid cystic carcinoma with perineural invasion treated by mohs micrographic surgery-a case report with literature review. J Oncol (2010) 0.89

T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity. Int Rev Immunol (2006) 0.88

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol (2009) 0.88

HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci (2003) 0.88

Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J Invest Dermatol (2007) 0.87

Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo. Exp Dermatol (2011) 0.85

Expression of angiopoietin-TIE system components in angiosarcoma. Mod Pathol (2013) 0.84

Atypical cellular disorders. Hematology Am Soc Hematol Educ Program (2002) 0.83

Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis. Am J Pathol (2013) 0.82

Renal angiomyolipoma, fat-poor variant--a clinicopathologic mimicker of malignancy. Virchows Arch (2013) 0.82

Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1. Arch Biochem Biophys (2011) 0.82

De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res (2009) 0.82

(V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. J Invest Dermatol (2011) 0.81

Quantitative gene analysis of methylation and expression (Q-GAME) in fresh or fixed cells and tissues. Exp Dermatol (2014) 0.81

Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis (2010) 0.80

Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model. Acta Derm Venereol (2016) 0.79

Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region. Pigment Cell Res (2004) 0.79

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother (2008) 0.79

Eccrine Porocarcinoma Treated by Mohs Micrographic Surgery: Over 6-Year Follow-up of 12 Cases and Literature Review. Dermatol Surg (2015) 0.79

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res (2014) 0.79

Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. In Vitro Cell Dev Biol Anim (2008) 0.79

KIT masters mast cells in kids, too. J Invest Dermatol (2010) 0.78

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res (2014) 0.78

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice. J Vis Exp (2015) 0.77

Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Exp Dermatol (2014) 0.75

Erratum: Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat Med (2017) 0.75

Vitiligo treatment demystified: a flowchart for stratified treatment approaches. Exp Dermatol (2014) 0.75

A generalized annular eruption with occasional vesicles. Arch Dermatol (2012) 0.75

TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold. Dermatol Online J (2017) 0.75

Generalized bullae in an infant. Arch Dermatol (2002) 0.75

Thrombotic lymphocytic vasculitic reaction to intravenous immunoglobulin. J Am Acad Dermatol (2006) 0.75

Correspondence: The association between morphea profunda and monoclonal gammopathy: A case series. Dermatol Online J (2016) 0.75

A 38-year-old woman with eyelid discoloration. Heliotrope-like manifestation of adult-onset Still disease (AOSD). Arch Dermatol (2012) 0.75

Serpiginous erythematous plaques on the feet. Arch Dermatol (2011) 0.75

Mohs surgical excision of a granular cell tumor with plexiform features on the arm of a 7-year-old child. Dermatol Surg (2010) 0.75

Black spots in the returning traveler. Dermatol Online J (2013) 0.75